Markets

Integrated Solutions for Monoclonal Antibodies (mAbs)

The biologics market is projected to grow at a double-digit compound annual growth rate of 15% until 2027[1], driven by the increasing adoption of advanced therapies such as monoclonal antibodies. As mAbs and other biologics become more complex, pharmaceutical companies need solutions that help protect drug stability, support reliable delivery, and reduce development risks.

Stevanato Group supports mAbs therapies with integrated solutions across the pharma value chain, combining:

Drug containment solutions to help preserve sensitive biologic formulations
Drug delivery devices to support reliable administration and patient adherence
Analytical services to evaluate drug-container-device compatibility, stability, and performance
Manufacturing equipment to support efficient production and scale-up
Inspection technologies to help ensure product quality and integrity

Together, these capabilities help pharmaceutical companies address the specific challenges of monoclonal antibodies, from early development to commercial manufacturing.

[1] Source: IQVIA and Stevanato Group internal analysis

mAbs drug features and key challenges

Monoclonal antibody formulations can be highly sensitive and, in some cases, highly concentrated. This makes them more exposed to potential drug-container interactions and requires careful evaluation of both primary packaging performance and delivery device functionality.

Key challenges include:

Stability, potency, and safety of drugs over time

Right first time development

Reliable delivery systems to improve therapy adherence

Higher concentration and injection volume

Stevanato Group is positioned to support mAbs production processes with comprehensive solutions covering the full pharma value chain. By combining drug containment expertise, analytical testing, device know-how, and manufacturing technologies, Stevanato Group helps customers address the specific requirements of sensitive biologic drugs.

Discover Stevanato Group solutions designed to support monoclonal antibodies and other sensitive biologics, from ready-to-use containment systems to analytical testing and advanced delivery technologies.